drugset / Trial / NCT00481455
Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the anti-tumor activity and safety of Panzem NCD given in combination with daily oral fixed-dose temozolomide in patients with recurrent glioblastoma multiforme.
Timeline
- Start
- 2007-04
- Primary completion
- 2007-09
- Completion
- 2008-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 2-methoxyestradiol | Small molecule | 2000 mg | Oral |
| Background | Temozolomide | Small molecule | — | Oral |